Asciminib for chronic myeloid leukemia in germany
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether the drug asciminib is safe and works well for people with chronic myeloid leukemia, compared to standard TKIs. You may join if you're newly diagnosed or have tried only one previous TKI treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old.
- Have a confirmed diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
- Be either newly diagnosed or have had only one prior TKI treatment (for asciminib group).
- Not have any BCR-ABL1 mutations that would make asciminib less effective.
- Not be currently participating in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This study looks at how well asciminib works in real-world patients with chronic myeloid leukemia who have already tried at least one other treatment. It aims to see how effective and safe it is in everyday practice.
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial tests a new pill, asciminib, as the first treatment for people newly diagnosed with chronic myeloid leukemia (CML) in its early phase. The goal is to see if it can control the disease with fewer side effects than standard treatments.
This trial lets people who already have Philadelphia chromosome–positive (Ph+) leukemia and are benefiting from asciminib (or certain related medicines) continue treatment. It mainly tests whether ongoing care in a follow-on study is safe and workable for participants.
Hear when a new Leukemia, Chronic Myeloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.